0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman)
(END) Dow Jones Newswires
November 21, 2024 09:16 ET (14:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.